Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at the upcoming Chardan Annual Genetic Medicines Conference at 8:30 a.m. ET on October 8th in New York, NY.
A live audio webcast of the Chardan presentation will be available on the Events page of the Investors section of the Company website. A replay of the Chardan presentation will also be archived for approximately 30 days on the Events & Presentations page.
About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.
Investor Contact:
Carlo Tanzi, Ph.D.
Kendall Investor Relations
617-337-4680
investors@solidbio.com
Media Contact:
Lindsay Deefholts
ScientPR
416-301-7966
media@solidbio.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
